reports
Satellos Bioscience Announces Partnership with Jesse's Journey
Toronto, Ontario--(Newsfile Corp. - September 7, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), and Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, are proud to announce a research partnership and infrastructure grant to support the development of Satellos' novel approach to treating Duchenne.Satellos scientists are developing small molecule drugs that they believe will restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug candidates regulate...
Satellos Bioscience Announces Second Quarter 2021 Financial Results an...
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics Inc. ("iCo"), today filed financial results and MD&A reports for the second quarter which ended on June 30, 2021, on SEDAR. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards.Satellos is developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne muscular dystrophy and potentially other degenerative muscle disorders...
Satellos Bioscience Announces High Resolution Crystal Structure of Duc...
Toronto, Ontario--(Newsfile Corp. - August 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos") announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal structure of their novel drug target for Duchenne muscular dystrophy ("Duchenne").Satellos scientists are developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug candidates regulate the activity of PTP-X, the codename for an enzyme which Satellos discovere...
Satellos Bioscience Announces Joint Development Agreement with NW Phar...
Toronto, Ontario--(Newsfile Corp. - August 18, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics, Inc., and NW PharmaTech Limited ("NW PharmaTech") announced today that Amphotericin B Technologies, Inc. ("AmpB Tech"), a wholly owned subsidiary of Satellos established to accelerate the development of its novel and proprietary oral transport technology ("OralTransTM"), has entered into a Joint Development Agreement with NW PharmaTech to develop an oral formulation of cannabidiol ("CBD") for the over-the-counter market. Oral CBD will initially target the global...
Satellos and iCo Announce Completion of Reverse Takeover
Toronto, Ontario--(Newsfile Corp. - August 13, 2021) - Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) ("Satellos" or the "Company") is pleased to announce the completion, following the receipt of the final order of the Supreme Court of British Columbia on August 5, 2021, and subject to the final approval of the TSX Venture Exchange (the "TSXV"), of the previously announced reverse takeover transaction which was completed by way of plan of arrangement under Section 192 the Canada Business Corporations Act (the "CBCA") involving Satellos Bioscience Inc. ("Pre-Arrangement ...
iCo Therapeutics Inc. Announces Shareholder Approval of Business Combi...
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that at an annual and special meeting of the Company held on August 3, 2021, shareholders of the Company have approved, among other matters, iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").The Company expects trading of the shares of the combined company to begin trading on the TSX Venture Exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of August 9, 2021.Wil...
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Appro...
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the "Exchange") of iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").The Company has filed an information circular on SEDAR (the "Circular") that describes the Transaction in detail and will be mailing the Circular to shareholders on or about July 13, 2021. iCo has set August 3, 2021 as the date of t...
iCo Therapeutics Announces First Quarter 2021 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We are very encouraged with our progress during the first quarter of 2021. We are working to complete our previously announced Arrangement with Satellos; we have raised C$7.25M in a private placem...
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-...
Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Amphotericin B Technologies, Inc ("Amp B Tech" or the "Company"), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) ("iCo"), announced today that two presentations related to research on the effectiveness of the Company's Oral Amphotericin B formulation ("iCo 019") on the SARS-Cov-2 virus have been accepted to the 2021 CSPS/PSJ/CC-CRS Joint Symposium - Pharmaceutical Sciences in a Pandemic World. The Symposium will be held virtually from May 31 to June 3, 2021 and is sponsored by the Canadian Society for Pharmaceut...
iCo Therapeutics Announces 2020 Year End Financial Results and Resigna...
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2021) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTC: ICOTF) today reported financial results for the year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").William Jarosz, CEO of iCo Therapeutics Inc., noted "We were very pleased by the progress of our Oral Amp B program during the year with our compound being safe and well tolerated in Phase 1b clinical trials and potential as a therapeutic agent for nove...
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receip...
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTC: ICOTF) ("iCo" or the "Company") is pleased to announce that it has closed its previously announced private placement (the "Financing") in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act. The completion of the Arrangement will result in the reverse takeover of the Company as defined in the policies of the TSX Venture Exchange...
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private P...
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that, in connection with its proposed business combination with Satellos Bioscience Inc. ("Satellos") by way of a plan of arrangement (the "Arrangement"), as previously announced on March 22, 2021, it intends to offer on a private placement basis (the "Financing") 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million, r...
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos B...
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo") and Satellos Bioscience Inc. ("Satellos"), a private Canadian corporation, together are pleased to announce the execution of a definitive agreement, dated March 21, 2021 (the "Arrangement Agreement"), providing for the business combination of iCo and Satellos by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act (the "CBCA"). Pursuant to the Arrangement, Satellos will become a wholly-owned subsidiary of iC...
iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-...
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2, the causative agent of COVID-19 in the hACE2 mouse model (the "iCo-019 Study"). iCo anticipates that the iCo-019 Study will be completed by the end of Q2 2021."We are excited for this next phase in our development of iCo-...
iCo Therapeutics Inc. Announces Warrant Exercises
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that between February 1, 2021 and March 12, 2021, 20,280,000 warrants of the Company were exercised for common shares in the capital of the Company resulting in proceeds to the Company of $1,301,200.00.William Jarosz, the Chief Executive Officer of iCo commented, "We deeply appreciate this show of support from our warrant holders. These funds will help us more rapidly advance strategic opportunities we've been pursuing." About iCo TherapeuticsiC...
iCo Therapeutics Inc: Unaware of Any Material Change
Vancouver, British Columbia--(Newsfile Corp. - February 25, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"). At the request of IIROC, iCo Therapeutics Inc. (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About iCo TherapeuticsiCo is Canadian biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat ocular and infectious diseases. For more information, v...
iCo Therapeutics Inc. Proposes to Re-Price Warrants
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted common share purchase warrants (the "Warrants") issued pursuant to a private placement of 25,000,000 units that was completed over several tranches from January 31, 2019 to March 4, 2019 (the "Spring 2019 Private Placement") and pursuant to a private placement of 41,200,000 units that closed on August 16, 2019 (the "S...
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount ...
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation. Skymount will initially commit up to $US 550,000 for pre-clinical work targeting the use of iCo-019 as a therapeutic product for infections relating to COVID-19."I am delighted that Skymount has recognized the potential we have created for iCo-0...
iCo Therapeutics Announces Third Quarter 2020 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We have aggressively continued to contain our operating expenses quarter over quarter and year over year. This has allowed us to increase the visibility of our iCo 019 program, continue o...
iCo Therapeutics Announces Option Grants
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today granted 1,535,000 stock options to directors, officers and a contractor.The stock options are exercisable at the price of $0.05 and will expire on October 25, 2025. The stock options shall vest as follows: 1/5 on today's date (the "Effective Date") and then 1/5 every six months until all options are vested. The closing price of the Company's shares on the TSX Venture Exchange on October 26, 2020 was $0.05. After giving effect to this option grant, a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.